期刊文献+

基于QbD理念优化伊潘立酮微球的冻干工艺 被引量:2

Study on Freeze-drying Process of Iloperidone PLGA Microspheres Base on QbD
下载PDF
导出
摘要 目的研究伊潘立酮聚乳酸-羟基乙酸共聚物(polylactic-co-glycolic acid,PLGA)微球的冻干工艺,优化工艺参数。方法以质量源于设计(QbD)理念进行工艺分析,使用JMP(11.2.0)软件进行实验设计及结果分析。结果样品水分的主要影响因素为一期干燥温度;样品二氯甲烷残留的影响因素为二期干燥温度及二期干燥真空度;样品有关物质的主要影响因素为二期干燥温度。结论预冻温度为-30℃,冻干时间为3 h,真空度为常压;一期干燥温度为-5℃,真空度为40 Pa,冻干时间为5 h;二期干燥温度为31~35℃,真空度为100Pa,冻干时间为10 h。 Objective To study the freeze-drying process and optimize the process parameters of iloperidone polylacticco-glycolic acid(PLGA)microspheres.Methods The freeze-drying process was analyzed by QbD.The experiments were designed and analyzed by JMP software(11.2.0).Results The main factors influencing the water content was the temperature of phase I.The solvent residue of the product was affected by the temperature and the vacuum of the phase II.The impurity of the sample was influenced by the temperature of the phase II.Conclusion The freeze-drying process of the microspheres was summarized as follows:in the pre-freezing step,the temperature was-30℃,and the pre-freezing time was not less than 3 h at atmospheric pressure;in drying phase I,the plate temperature was-5℃,the vacuum degree was 30-50 Pa and the freeze-drying time was not less than 5 h;in drying phase II,the plate temperature was 31-35℃,the vacuum degree was 100 Pa and freeze-drying time was not less than 10 h.
作者 鲍菲 孙翠香 高飞 于洪云 李又欣 BAO Fei;SUN Cui-xiang;GAO Fei;YU Hong-yun;LI You-xin(School of Pharmacy,Yantai University,Yantai 264000,China;Shandong Luye Pharmaceutical Co.,Ltd.,Yantai 264000,China)
出处 《食品与药品》 CAS 2018年第2期97-101,共5页 Food and Drug
关键词 伊潘立酮 聚乳酸-羟基乙酸共聚物微球 冻干 实验设计 质量源于设计 iloperidone PLGA microsphere freeze-drying design of experiment quality by design
  • 相关文献

参考文献4

二级参考文献50

  • 1曹同玉,戴兵,戴俊燕.单分散大粒径聚合物微球的合成及应用[J].高分子通报,1995(3):174-180. 被引量:42
  • 2FDA. Full preseribing information for Fanapt[ EB/OL]. [ 2009 - 05-06]. http: //www. accessdata. fda. gov/drugsatfda docs/ label/2009/022192 lbl. pdf.
  • 3KALKMAN HO, SUBRAMANIAN N, HOYER D. Extended radioligand binding profile of iloperidone : a broad spectrum dopamine/ serotonin/norepinephrine receptor antagonist for the management of psychotic disorders [ J ]. Neuropsychopharmacology, 2001,25 ( 6 ) :904 -914.
  • 4SZEWCZAK MR, CORBETT R, RUSH DK, et al. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent [ J]. J Pharmacol Exp Ther, 1995,274( 3 ) : 1404 - 1413.
  • 5SUBRAMANIAN N, KALKMAN HO. Receptor profile ofP88- 8991 and P95412113, metabolites of the novel antipsychotic iloperidone [ J ]. Prog Neuropsychopharmacol Biol Psychiatry, 2002, 26(3): 553-560.
  • 6SAINATI SM, HUBBARD JW, CHI E, et al. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic [ J]. J Clin Pharmacol, 1995,35(7) :713 -720.
  • 7POTKIN SG, LITMAN RE, TORRES R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies [ J ]. J Clin Psychopharmacol, 2008,28 ( 2 Suppl 1 ) : S4 - S11.
  • 8CUTLER AJ, KALALI AH, WEIDEN PJ, et al. Four week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia[ J]. J Clin Psychopharmacol,2008,28 ( 2 Suppl 1 ) : S20 -S28.
  • 9KANE JM, LAURIELLO J, LASKA E, et al. Long term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia [ J ]. J Clin Psychopharmacol,2008,28 (2 Suppl 1 ) : S29 -S35.
  • 10Baumeister P W. Optical absorption of cuprous oxide. Phys Rev, 1961, 121:359.

共引文献30

同被引文献11

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部